Title: Efficacy and Safety of Addition of Teneligliptin to Type 2 Diabetes Patients Inadequately Controlled with Triple Drug Treatment with Glimepride + Metformin + Voglibose
Author: Dr SR Patnaik
DOI: https://dx.doi.org/10.18535/jmscr/v6i3.17
Abstract
Type 2 diabetes is a significant health problem and its prevalence is increasing globally. There are several challenges to the management of type 2 diabetes in the Indian population. A single-center study evaluated the efficacy and safety of addition of teneligliptin 20 mg/day to type 2 diabetes patients inadequately controlled with triple drug treatment with glimepride + metformin + voglibose. Overall, 81 were prescribed teneligliptin in addition to triple drug treatment. At study end, 62.12% patients achieved HbA1c levels <7%. Patients reported only mild/transient adverse effects during the study period. It was concluded that addition of teneligliptin to triple drug therapy with glimepride + metformin + voglibose is efficacious to attain HbA1c below 7% in diabetes patients inadequately controlled with the triple therapy. It is also a safe drug since the adverse effects reported following the addition of teneligliptin were mild/transient.
Keywords: Teneligliptin, type 2 diabetes, triple drug therapy.
References
- Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ. 2015; 3: e1461.
- Available from: https://www.idf.org/our-network/regions-members/south-east-asia/members/94-india.html. Accessed on February 23, 2018.
- Ramachandran A, Shetty AS, Nanditha A, Snehalatha C. Type 2 Diabetes in India: Challenges and Possible Solutions. Available from: http://www.apiindia.org/medicine_update_2013/chap40.pdf. Accessed on February 23, 2018.
- Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018 Jan; 41(Supplement 1): S73-S85.
- Torre EM, Tejedor JL, Menendez SA, et al. Recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes. Consensus document. Nefrologia (English Version) 2011;31:17-26.
- Sharma SK, Panneerselvam A, Singh KP, et al. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016; 9: 251–260.
- Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012 Nov;14(11):1040-6.
- Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Sep;15(9):810-8.
- Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab. 2015 Mar;17(3):309-12.